Financings Of The Fortnight Sees The Blooming Of New Life Sciences Funding Sources In The EU
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financing activity by Aastrom Biosciences, Tarsa Therapeutics, OncoGenex and Medivation.
You may also be interested in...
Aastrom Stands Behind Its Decision To Shift Gears In Late Stages
The Michigan biotech is undergoing a complete restructuring as it cans its lead program and new management implements a different vision for the company.
Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.
OncoGenex Raises Cash For Prostate Cancer Trials
OncoGenex raises $50 million in cash to support the development of its earlier stage oncology assets.